M. Majem, M. Garassino, C. Dooms, E. Eigendorff, G.L. Martinengo, O. Bylicki, D. Rodriguez Abreu, S. Novello, E. Nadal, A. Lowczak, D. De Almeida Matias, A. Luft, B. Mennecier, A. Rittmeyer, E. Jensen, S. Keller, Ayman Samkari, J. Spicer
In the phase 3 KEYNOTE-671 study of early-stage NSCLC, perioperative pembro plus neoadjuvant chemotherapy (chemo) significantly improved event-free survival (EFS), overall survival (OS), major pathological response, and pCR vs neoadjuvant chemo. EFS was prolonged in exploratory analyses of participants (pts) who achieved pCR (HR, 0.33; 95% CI, 0.09–1.22). We report efficacy results in pts with pCR from KEYNOTE-671 after 5 years of follow-up.